Trial intelligence / Profile preview

MODERNIZE 1: siplizumab versus rabbit anti-thymocyte globulin for kidney transplant induction

2026-525646-29-00Phase 2Authorised

Sponsor: Nefro Avillion Clinical Development Limited
Start: Sep 2026
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 6

Overview

Phase 2, randomised, double-blind trial of siplizumab in kidney allograft rejection (2 arms), sponsored by Nefro Avillion Clinical Development Limited. Primary endpoint: Safety at 12 months post-transplant. Planned start Sep 2026; status: authorised.

Drugs

siplizumab

Conditions

kidney allograft rejection

Beyond the preview

Go deeper on 2026-525646-29-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2026-525646-29-00.